HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs

This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.

By KFF Health News · May 8, 2026 · via KFF Health News
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs

Image: KFF Health News

This is an aggregated industry headline. Read the full story at KFF Health News

Tags
policyformat:headlineheadlineKFF Health News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
PolicyFiercePharma ↗
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepr…
May 9, 2026
Japan’s FY26 price revision expands G1 repricing and drives price reduction
PolicyPharmaceutical Technology ↗
Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices…
May 8, 2026
STAT+: More political interference at the FDA?
PolicySTAT News ↗
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newslet…
May 7, 2026